RYTMRhythm Pharmaceuticals, Inc.

$6B

Q3 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$37M

Net Income

-$36M

EPS (Diluted)

$-1.04

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$34M

Free Cash Flow

-$34M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$178M

Total Liabilities

$28M

Stockholders' Equity

$149M

Cash & Equivalents

$72M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$37M	-$19M	-92.8%
Net Income	-$36M	-$18M	-103.6%

RYTM Q3 2019 Earnings — Rhythm Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena